NCT02930109 - A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2016

Primary Completion Date

October 31, 2023

Study Completion Date

March 4, 2024

Conditions

Acute Leukemia

Interventions

DRUG

PTX-200

During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on Day 1 each cycle. Triciribine will be infused over 1 hour on Day 1 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2

DRUG

Cytarabine

Cytarabine will be given at a dose of 400 mg/m2 as a continuous IV infusion on days 3-7 of each cycle.

Trial Locations (2)

33612

Moffitt Cancer Center, Tampa

60069

University of Kansas Cancer Center, Fairway